ArticleJournal of cardiothoracic surgery2025
Screening telomere-related genes to predict prognosis, immunotherapy response, and drug sensitivity in esophageal cancer using a machine learning approach.
Article in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEsophageal cancer (EC) is a common malignancy with poor prognosis. Telomeres, composed of repetitive DNA sequences and shelterin complexes, play important roles in tumor biology. However, the prognostic value of telomere-related genes (TRGs) in EC remains unclear.
methodsTRGs were obtained from TelNet, and transcriptomic and clinical data were collected from The Cancer Genome Atlas (TCGA). Prognostic TRGs were identified using multivariate Cox regression analysis, Least Absolute Shrinkage and Selection Operator (LASSO), Random Forest (RF), and Support Vector Machine (SVM) algorithms to construct a risk model. Model performance was evaluated by Kaplan-Meier(K-M) and Receiver Operating Characteristic (ROC) analyses, and a nomogram integrating clinical variables was developed. Somatic mutations, immune infiltration, immunotherapy response, and drug sensitivity were compared between high- and low-risk groups. In addition, functional assays were performed to verify the biological role of the key gene PTGES3.
resultsSix TRGs significantly associated with prognosis were identified to establish a risk model. High-risk patients had worse survival, higher TP53 and TTN mutation rates, altered immune infiltration, poorer predicted immunotherapy response, and distinct drug sensitivity profiles. Knockdown of PTGES3 significantly suppressed EC cell migration, invasion, and clonogenic ability, supporting its oncogenic role.
conclusionA TRGs-based prognostic model effectively predicts survival in EC and reveals associations with somatic mutations, immune infiltration, and drug sensitivity. Functional validation of PTGES3 further supports its potential as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.